Read/Post Comments (0) | Recommended this article (0)
Please login to Zacks.com or register to post a comment.
Zacks' 7 Best Stocks
for June, 2013
FREE Report for Zacks.com
Visitors Only
Visitors Only
They're hand-picked from the list of Zacks Rank #1 Strong Buys. Our experts predict that their prices will jump the soonest.
Today, you can see them free.
- Latest News
- Most Popular
- Roundtable Top Picks of the Week
- FED Front & Center Again
- RTI: Sector Strength Charts - Where's the Opportunity Now?
- Surging Financial ETFs Beating the Market
- Utility Industry Stock Outlook - June 2013
- 3 Japanese Stocks to Buy Now
- Your Next Stock Should Be Making New Highs
- Anatomy of Success: Stoneridge (SRI)
- RTI: What Will the Fed Do Wednesday?
- AWS 6/18: Can the Fed Afford to Keep the Suspense?
- PFP 6/18: Wednesday Fed Watch
Recent Quotes
| No Recent Quote currently available |
My Portfolio
|
My Portfolio Tracker One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts. Set yours up today. |
More Zacks Resources
Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.
Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.
Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.
My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.
Zacks #1 Stocks on the Move 06/18/2013
| Company Name | Symbol | %Change |
|---|---|---|
| STAAR SURGIC | STAA | 10.98% |
| DTS INC | DTSI | 6.89% |
| ANIKA THERAP | ANIK | 6.04% |
| LUMOS NETWOR | LMOS | 5.70% |
| INSTEEL IND | IIIN | 5.28% |
Quick Links
Resources
Client Support
Zacks Research is Reported On:
Zacks Investment Research
is an A+ Rated BBB
Accredited Business.
Copyright 2013 Zacks Investment Research
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1986 it has nearly tripled the S&P 500 with an average gain of +26% per year. These returns cover a period from 1986-2011 and were examined and attested by Baker Tilly, an independent accounting firm.
Visit performance for information about the performance numbers displayed above.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This page is temporarily not available. Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext. 9339.
Q4 Revenue Guidance Revised Upwards
Brian Marckx, CFA
Corgenix Medical (CONX) announced on 7/3/12 that fiscal Q4 (ending 6/30/12) revenue is expected to be approximately $2.3MM, or about $170k (8%) higher than previously anticipated. $2.3MM in Q4 will push fiscal 2012 revenue to almost $9.3MM, up 17% from 2011. While not specifically stated in the press release, the implication is that the upward revenue revision may relate to stronger than expected contract manufacturing revenue in Q4. Contract manufacturing has been the single biggest catalyst of CONX's revenue growth through the first nine months of fiscal 2012 (compared to the same period in 2011), contributing more than one-half of the 25% growth over that period.
Specifically related to CONX's contract manufacturing business, in June the company announced a five year manufacturing and supply agreement with diaDexus. Under the deal, Corgenix will manufacture and supply the PLAC test, a cardiovascular assay that measures LP-PLA2, a marker which recently got an endorsement from the American Association of Clinical Endocrinologists when they added it to their recommended list of tests for heart disease.
Prior to the revised revenue guidance we were modeling Q4 and FY2012 revenue of $2.16MM and $9.12MM, we've now moved our numbers to $2.33MM and $9.29MM. Our Q4 and FY2012 EPS estimates remain unchanged (-$0.00, -$0.01). We have also made no material adjustments to the remainder of our model.
We are maintaining our Outperform rating and $0.50 price target on CONX.
Please visit scr.zacks.com to access a complimentary copy of the full CONX research report.
Get the full on CONX - FREE